Compare GSK plc (GSK) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs IQIYI Inc - ADR — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while IQIYI Inc - ADR trades at $1.24 (market cap $1.15B). The key difference: GSK plc is far larger — about 88.1× IQIYI Inc - ADR's market cap, and GSK plc pays a 3.49% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| GSK | IQ | |
|---|---|---|
Market Cap | $101.34B | $1.15B |
Sector | Health | Media |
52-Week High | $61.18 | $2.79 |
52-Week Low | $36.20 | $0.96 |
Enterprise Value | $121.95B | $2.71B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
IQ (iQIYI) trades at $1.16, up 2.65% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion, though it beat EPS expectations in two of the last three quarters. Recent news highlights AI platform growth and leadership changes as potential turnaround catalysts.
The outlook is mixed: analyst consensus leans buy (50%) with price predictions citing upside potential, but profitability challenges and revenue declines pose risks. Investment opportunity hinges on AI-driven content innovation offsetting competitive pressures in China's streaming market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
